| Issue | Title | |
| Vol 2011, No 10 (2011) | Galapagos and Servier Form Multiyear Cancer Therapeutics Partnership | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 102 (2008) | Galapagos Diversifies into Antibodies | Abstract html |
| Sally Mardikian PhD | ||
| Vol 2006, No 73 (2006) | Galapagos Goes from Strength to Strength | Abstract |
| Business Review Editor | ||
| Vol 2012, No 3 (2012) | Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 66 (2005) | Galapagos NV | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Galapagos' Latest Advance: Its Licensing Deal with Janssen | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 65 (2005) | Galapagos: An Evolving Company | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 94 (2008) | Galderma Acquires CollaGenex | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 34 (2003) | Galen Chemicals Proposes Acquisition of Women’s Healthcare Products from Pfizer | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 89 (2007) | Galenica Acquires Aspreva for US$915 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 8 (2016) | Galenica Acquires Relypsa to Bolster Its Cardio-Renal Portfolio | Abstract pdf html |
| Subham Nandi & Dan Roberts | ||
| Vol 2008, No 93 (2008) | GE Healthcare Acquires Whatman | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 10 (2010) | GE Healthcare and Janssen to Develop Biosignatures for Alzheimer’s Disease | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 1 (2014) | GE Healthcare Strengthens Life Sciences Division by Acquiring Three Businesses from Thermo Fisher Scientific | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 9 (2010) | GE Healthcare to Acquire Clarient and Accelerate Expansion into Cancer Diagnostics | Abstract |
| Editorial Team | ||
| Vol 2002, No 27 (2002) | Gedeon Richter Ltd | Abstract |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | Genasense (oblimersen sodium) | Abstract pdf |
| Business Review Editor | ||
| Vol 2015, No 3 (2015) | Gene Therapy Start-Up Voyager Therapeutics Impresses with US$845 M Genzyme Deal | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 45 (2004) | Genelab’s Lupus Drug Enters Japanese Market | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 6 (2012) | Genentech and AC Immune Partner Again in Alzheimer’s Disease | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 9 (2016) | Genentech and BioNTech to Collaborate on mRNAVaccines | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2019, No 5 (2019) | Genentech and Parvus Therapeutics Collaborate on Autoimmune Diseases | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 6 (2021) | Genentech and Pieris Collaborate on Respiratory and Ophthalmology Therapies | Abstract pdf html |
| Michelle Liu | ||
| Vol 2008, No 101 (2008) | Genentech and Roche Sign Deal for GlycArt’s Anticancer Antibody Therapy | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2012, No 6 (2012) | Genentech Becomes Ensemble Therapeutics’ Third Big Pharma Collaborator on Macrocyclic Drug Discovery | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 7 (2011) | Genentech Gain Rights to Acquire Forma Therapeutics’ Preclinical Cancer Programme in Innovative Deal | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 7 (2019) | Genentech on a Discovery Spree with Skyhawk, Convelo and Sosei Heptares Deals | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 1 (2021) | Genentech Partners with Ribometrix in US$1 B RNA Therapeutics Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2023, No 10 (2023) | Genentech Pays Orionis US$47 M Upfront for Molecular Glue Medicines | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2020, No 8 (2020) | Genentech Pays US$120 M Upfront for UCB’s Tau-targeting Antibody UCB0107 | Abstract html pdf |
| Michelle Liu | ||
| Vol 2019, No 1 (2019) | Genentech Pushes for Leadership in Cancer Diagnostics with Adaptive Biotechnologies Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2024, No 10 (2024) | Genentech to Acquire Regor Therapeutics’ CDK Inhibitors for US$850 M Upfront | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2003, No 41 (2003) | General Electric in Amersham Takeover | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 3 (2019) | General Electric to Sell Biopharma Business to Danaher for US$21.4 B | Abstract html pdf |
| Michelle Liu | ||
| Vol 2022, No 7 (2022) | Generian and Mitobridge Form Alliance to Develop Novel Small Molecules for Undruggable Targets | Abstract pdf html |
| Swati Sharan | ||
| Vol 2005, No 60 (2005) | Generics Companies: Moving Up the Food Chain | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | GeneSoft Licenses Rights to Factive from LG Life Sciences | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 40 (2003) | Genestream Pty Ltd | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 73 (2006) | Genetic Technologies Enters into Agreements for Australian and Chinese Territories | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 9 (2022) | Genfit Buys Versantis to Rebuild its Liver Disease Portfolio | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2024, No 4 (2024) | Genmab Acquires ADC Drug Developer ProfoundBio for US$1.8 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2014, No 10 (2014) | Genmab Forms Third Antibody-Drug Conjugate Pact with Seattle Genetics | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 7 (2012) | Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 60 (2005) | Genmab Licenses Preclinical-Stage Antibody to Serono | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 1 (2022) | Genmab Licenses Synaffix’s Antibody-Drug Conjugate Technologies | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 7 (2018) | Genmab Partners With Immatics To Discover and Develop Next-Generation Immunotherapies | Abstract pdf html |
| Michelle Liu | ||
| Vol 2012, No 9 (2012) | Genmab Signs US$1.1 B Daratumumab Licence Agreement with Janssen Biotech | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 6 (2012) | Genmab’s DuoBody™ Technology Gains Validation with Novartis Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 29 (2002) | GenStar Therapeutics and Vascular Genetics Announce Merger | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 32 (2003) | GenVec and Fuso in Cancer Research Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 102 (2008) | Genzyme and Osiris Sign Deal for First-in-Class Adult Stem Cell Products | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2003, No 39 (2003) | Genzyme Expands Immunology Portfolio Through Sangstat Acquisition | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 3 (2011) | Genzyme Finally Agrees to US$20.1 B Plus CVR Takeover by Sanofi-aventis | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 92 (2008) | Genzyme Goes Mainstream | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 2 (2014) | Genzyme Invests US$700 M in Alnylam in Sign of Resurgent Interest in RNAi Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 55 (2005) | Genzyme Reacquires Arthritis Pain Treatment from Wyeth | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Genzyme to Acquire Bioenvision | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 87 (2007) | Gepirone ER | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 89 (2007) | Getting Real or Keeping It Real? | Abstract |
| Business Review Editor | ||
| Vol 2004, No 51 (2004) | Getting the Deal Value Right! | Details html |
| Fintan Walton | ||
| Vol 2007, No 84 (2007) | Geymonat SpA | Abstract |
| Business Review Editor | ||
| Vol 2005, No 57 (2005) | Giant Pfizer to Acquire Tiny Angiosyn | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 8 (2017) | Gilead Acquires CAR-T Oncology Specialist Kite for US$11.9 B | Abstract pdf html |
| Daniel Roberts | ||
| Vol 2020, No 3 (2020) | Gilead Acquires CD47 Focused Forty Seven for US$4.9 B | Abstract html pdf |
| Michelle Liu | ||
| Vol 2016, No 4 (2016) | Gilead Acquires NASH Candidate from Nimbus to Strengthen its Liver Disease Portfolio | Abstract pdf html |
| Taskin Ahmed & Keshav Mahawar | ||
| Vol 2004, No 53 (2004) | Gilead and Genelabs Form Hepatitis C Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 5 (2020) | Gilead and Second Genome Sign US$1.5 B Microbiome-based Drug Discovery Deal | Abstract pdf html |
| Sasha Yachu & Michelle Liu | ||
| Vol 2011, No 7 (2011) | Gilead and Tibotec Partner to Develop and Commercialise HIV Combination Drugs | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 59 (2005) | Gilead Begins to Fill the Hole in its Pipeline | Abstract |
| Business Review Editor | ||
| Vol 2011, No 12 (2101) | Gilead Bets on Pharmasset with US$11 B Acquisition Agreement | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 11 (2018) | Gilead Boosts Oncology Pipeline with Tango Collaboration | Abstract pdf html |
| Michelle Liu | ||
| Vol 2020, No 1 (2020) | Gilead Collaborates with Kyverna Therapeutics on T-cell Therapies | Abstract html pdf |
| Pratika Pahwa | ||
| Vol 2024, No 3 (2024) | Gilead Collaborates with Merus For Novel Antibody-Based Trispecific T-Cell Engagers | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2020, No 9 (2020) | Gilead Continues Immuno-oncology Spree with US$21 B Immunomedics Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2011, No 3 (2011) | Gilead Continues its Diversification Strategy with Acquisition of Calistoga Pharmaceuticals | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 6 (2020) | Gilead Continues Oncology Spree with US$2.2 B Arcus Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 7 (2019) | Gilead Deepens R&D Investment with US$10 B Galapagos Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2020, No 8 (2020) | Gilead Expands Deal and Triples Tango Targets to 15 | Abstract pdf html |
| Michelle Liu | ||
| Vol 2015, No 1 (2015) | Gilead Expands Liver Disease Pipeline by Purchasing Phenex’s Farnesoid X Receptor Programme | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 5 (2019) | Gilead Forms Kidney Disease Pact with Goldfinch Bio | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 6 (2019) | Gilead Joins Growingly Crowded Protein Degradation Field with Nurix Therapeutics Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2016, No 2 (2016) | Gilead Lands Galapagos’ Filgotinib After AbbVie Walks Away | Abstract pdf html |
| Heather Cartwright & Keshav Mahawar | ||
| Vol 2011, No 10 (2011) | Gilead Licenses Boehringer Ingelheim’s NCINI Inhibitors for HIV | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 4 (2019) | Gilead Looks to Machine Learning with insitro NASH Collaboration | Abstract pdf html |
| Michelle Liu | ||
| Vol 2020, No 12 (2020) | Gilead Makes Virology Bet with MYR Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 77 (2006) | Gilead Pays 50% Premium for Myogen | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 3 (2009) | Gilead Rescues CV Therapeutics | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 4 (2011) | Gilead Sciences and Yale School of Medicine in Potential US$100 M Cancer Research Pact | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | Gilead Sciences Diversifies into Kinase Biology | Abstract |
| Staff Editor | ||
| Vol 2009, No 7 (2009) | Gilead Signs Triple Therapy Deal for HIV | Abstract |
| Taskin Ahmed | ||
| Vol 2019, No 1 (2019) | Gilead Signs US$1.53 B Deal with Scholar Rock to Strengthen its Fibrotic Diseases Pipeline | Abstract html pdf |
| Sharath Chandra Nakka & Michelle Liu | ||
| Vol 2022, No 10 (2022) | Gilead Signs US$1.7 B Deal with MacroGenics for Bispecific Antibodies | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2011, No 1 (2011) | Gilead Strengthens its Early-Stage Pipeline by Acquiring Arresto Biosciences | Abstract |
| Heather Cartwright | ||
| Vol 2024, No 3 (2024) | Gilead to Acquire CymaBay Therapeutics and its Liver Disease Drug for US$4.3 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2013, No 1 (2013) | Gilead to Strengthen Oncology Pipeline with YM BioSciences Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 3 (2018) | Gilead’s Kite Signs US$3.15 B Genome Editing Deal with Sangamo | Abstract pdf html |
| Heather Cartwright | ||
| Vol 2021, No 7 (2021) | Gilead’s Kite to Collaborate with Shoreline for CAR NK Therapies | Abstract pdf html |
| Shikha Kashyap | ||
| Vol 2022, No 6 (2022) | GlaxoSmithKline Acquires Affinivax for US$3.3 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2007, No 79 (2007) | GlaxoSmithKline Acquires Next-Generation Antibody Company Domantis | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | GlaxoSmithKline Advances Sales Growth in Latin America with Acquisition of Laboratorios Phoenix | Abstract |
| Heather Cartwright | ||
| 1101 - 1200 of 2581 Items | << < 7 8 9 10 11 12 13 14 15 16 > >> | |